CD274 and neoplasm: Currently, several biomarkers are used in clinical practice to guide ICI use, including programmed death-ligand 1 (PD-L1) expression, mismatch repair (MMR) or microsatellite instability (MSI) status, and tumor mutational burden (TMB).